View in EDS HTML Full Text PDF Full Text

Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study.

Saved in:
Bibliographic Details
Title: Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study.
Authors: Cohen G; Mary Potter Oncology Centre, Pretoria, South Africa., Rapoport B; The Medical Oncology Centre of Rosebank, Johannesburg, South Africa.; Department of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa., Chan SW; Sandton Oncology, Johannesburg, South Africa., Ruff P; University of Witwatersrand Faculty of Health Sciences, Johannesburg, South Africa., Arance A; Hospital Clínic de Barcelona, Barcelona, Spain., Mujika Eizmendi K; Onkologikoa Donostia, San Sebastian, Spain., Houghton B; Port Macquarie Base Hospital, Port Macquarie, New South Wales, Australia., Brown MP; Cancer Clinical Trials Unit, Royal Adelaide Hospital, and School of Medicine, The University of Adelaide, Adelaide, South Australia, Australia., Zielinski RM; Central West Cancer Care Centre, Orange Hospital, Orange, New South Wales, Australia.; Western Sydney University, Sydney, New South Wales, Australia., Muñoz Couselo E; Department of Medical Oncology, Melanoma and Other Skin Cancers Unit, Vall d'Hebron University Hospital, Barcelona, Spain., Lyle M; Liz Plummer Cancer Care Centre, Cairns, Queensland, Australia., Anderson JR; Merck & Co., Inc., Rahway, New Jersey, United States of America., Jain L; Merck & Co., Inc., Rahway, New Jersey, United States of America., de Alwis D; Merck & Co., Inc., Rahway, New Jersey, United States of America., Lala M; Merck & Co., Inc., Rahway, New Jersey, United States of America., Akala O; Merck & Co., Inc., Rahway, New Jersey, United States of America., Chartash E; Merck & Co., Inc., Rahway, New Jersey, United States of America., Jacobs C; Cancer Care: Clinical & Radiation Oncology, Cape Town, South Africa.
Source: PloS one [PLoS One] 2024 Nov 12; Vol. 19 (11), pp. e0309778. Date of Electronic Publication: 2024 Nov 12 (Print Publication: 2024).
Publication Type: Journal Article; Clinical Trial, Phase I; Multicenter Study
Journal Info: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39531423
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Cohen+G%22">Cohen G</searchLink>; Mary Potter Oncology Centre, Pretoria, South Africa.<br /><searchLink fieldCode="AU" term="%22Rapoport+B%22">Rapoport B</searchLink>; The Medical Oncology Centre of Rosebank, Johannesburg, South Africa.; Department of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.<br /><searchLink fieldCode="AU" term="%22Chan+SW%22">Chan SW</searchLink>; Sandton Oncology, Johannesburg, South Africa.<br /><searchLink fieldCode="AU" term="%22Ruff+P%22">Ruff P</searchLink>; University of Witwatersrand Faculty of Health Sciences, Johannesburg, South Africa.<br /><searchLink fieldCode="AU" term="%22Arance+A%22">Arance A</searchLink>; Hospital Clínic de Barcelona, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Mujika+Eizmendi+K%22">Mujika Eizmendi K</searchLink>; Onkologikoa Donostia, San Sebastian, Spain.<br /><searchLink fieldCode="AU" term="%22Houghton+B%22">Houghton B</searchLink>; Port Macquarie Base Hospital, Port Macquarie, New South Wales, Australia.<br /><searchLink fieldCode="AU" term="%22Brown+MP%22">Brown MP</searchLink>; Cancer Clinical Trials Unit, Royal Adelaide Hospital, and School of Medicine, The University of Adelaide, Adelaide, South Australia, Australia.<br /><searchLink fieldCode="AU" term="%22Zielinski+RM%22">Zielinski RM</searchLink>; Central West Cancer Care Centre, Orange Hospital, Orange, New South Wales, Australia.; Western Sydney University, Sydney, New South Wales, Australia.<br /><searchLink fieldCode="AU" term="%22Muñoz+Couselo+E%22">Muñoz Couselo E</searchLink>; Department of Medical Oncology, Melanoma and Other Skin Cancers Unit, Vall d'Hebron University Hospital, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Lyle+M%22">Lyle M</searchLink>; Liz Plummer Cancer Care Centre, Cairns, Queensland, Australia.<br /><searchLink fieldCode="AU" term="%22Anderson+JR%22">Anderson JR</searchLink>; Merck & Co., Inc., Rahway, New Jersey, United States of America.<br /><searchLink fieldCode="AU" term="%22Jain+L%22">Jain L</searchLink>; Merck & Co., Inc., Rahway, New Jersey, United States of America.<br /><searchLink fieldCode="AU" term="%22de+Alwis+D%22">de Alwis D</searchLink>; Merck & Co., Inc., Rahway, New Jersey, United States of America.<br /><searchLink fieldCode="AU" term="%22Lala+M%22">Lala M</searchLink>; Merck & Co., Inc., Rahway, New Jersey, United States of America.<br /><searchLink fieldCode="AU" term="%22Akala+O%22">Akala O</searchLink>; Merck & Co., Inc., Rahway, New Jersey, United States of America.<br /><searchLink fieldCode="AU" term="%22Chartash+E%22">Chartash E</searchLink>; Merck & Co., Inc., Rahway, New Jersey, United States of America.<br /><searchLink fieldCode="AU" term="%22Jacobs+C%22">Jacobs C</searchLink>; Cancer Care: Clinical & Radiation Oncology, Cape Town, South Africa.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101285081%22">PloS one</searchLink> [PLoS One] 2024 Nov 12; Vol. 19 (11), pp. e0309778. <i>Date of Electronic Publication: </i>2024 Nov 12 (<i>Print Publication: </i>2024).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase I; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Public+Library+of+Science%22">Public Library of Science </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101285081 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>1932-6203 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2219326203%22">19326203 </searchLink><i>NLM ISO Abbreviation: </i>PLoS One <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39531423
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1371/journal.pone.0309778
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: e0309778
    Titles:
      – TitleFull: Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Cohen G
      – PersonEntity:
          Name:
            NameFull: Rapoport B
      – PersonEntity:
          Name:
            NameFull: Chan SW
      – PersonEntity:
          Name:
            NameFull: Ruff P
      – PersonEntity:
          Name:
            NameFull: Arance A
      – PersonEntity:
          Name:
            NameFull: Mujika Eizmendi K
      – PersonEntity:
          Name:
            NameFull: Houghton B
      – PersonEntity:
          Name:
            NameFull: Brown MP
      – PersonEntity:
          Name:
            NameFull: Zielinski RM
      – PersonEntity:
          Name:
            NameFull: Muñoz Couselo E
      – PersonEntity:
          Name:
            NameFull: Lyle M
      – PersonEntity:
          Name:
            NameFull: Anderson JR
      – PersonEntity:
          Name:
            NameFull: Jain L
      – PersonEntity:
          Name:
            NameFull: de Alwis D
      – PersonEntity:
          Name:
            NameFull: Lala M
      – PersonEntity:
          Name:
            NameFull: Akala O
      – PersonEntity:
          Name:
            NameFull: Chartash E
      – PersonEntity:
          Name:
            NameFull: Jacobs C
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 12
              M: 11
              Text: 2024 Nov 12
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 1932-6203
          Numbering:
            – Type: volume
              Value: 19
            – Type: issue
              Value: 11
          Titles:
            – TitleFull: PloS one
              Type: main
ResultId 1